Prognostic value of plasma fibroblast growth factor 21 among patients with acute ischemic stroke

To evaluate the association between plasma fibroblast growth factor 21 (FGF‐21) and clinical outcomes in patients with acute ischemic stroke.

[1]  Ming Liu,et al.  Stroke in China: advances and challenges in epidemiology, prevention, and management , 2019, The Lancet Neurology.

[2]  Feng Liu,et al.  Erratum. Serum FGF21 Levels Are Increased in Obesity and Are Independently Associated With the Metabolic Syndrome in Humans. Diabetes 2008;57:1246–1253 , 2018, Diabetes.

[3]  A. Suksamrarn,et al.  Dihydrocapsaicin Attenuates Blood Brain Barrier and Cerebral Damage in Focal Cerebral Ischemia/Reperfusion via Oxidative Stress and Inflammatory , 2017, Scientific Reports.

[4]  Y. Asano,et al.  Association between circulating fibroblast growth factor 21 and mortality in end-stage renal disease , 2017, PloS one.

[5]  F. Gómez-Pérez,et al.  Fibroblast growth factor 21 and its novel association with oxidative stress , 2016, Redox biology.

[6]  D. Chuang,et al.  Tubastatin A, an HDAC6 inhibitor, alleviates stroke-induced brain infarction and functional deficits: potential roles of α-tubulin acetylation and FGF-21 up-regulation , 2016, Scientific Reports.

[7]  A. Keech,et al.  The relationship of fibroblast growth factor 21 with cardiovascular outcome events in the Fenofibrate Intervention and Event Lowering in Diabetes study , 2015, Diabetologia.

[8]  J. Chen,et al.  Effects of immediate blood pressure reduction on death and major disability in patients with acute ischemic stroke: the CATIS randomized clinical trial. , 2014, JAMA.

[9]  Andrew E Moran,et al.  Global and regional burden of first-ever ischaemic and haemorrhagic stroke during 1990–2010: findings from the Global Burden of Disease Study 2010 , 2013, The Lancet. Global health.

[10]  B. Cheung,et al.  Serum Fibroblast Growth Factor-21 Levels Are Associated With Carotid Atherosclerosis Independent of Established Cardiovascular Risk Factors , 2013, Arteriosclerosis, thrombosis, and vascular biology.

[11]  A. Nowakowski,et al.  Serum fibroblast growth factor 21 is predictive of combined cardiovascular morbidity and mortality in patients with type 2 diabetes at a relatively short-term follow-up. , 2013, Diabetes research and clinical practice.

[12]  Xiu-Ling Deng,et al.  Oxidative stress impairs IKCa- and SKCa-mediated vasodilatation in mesenteric arteries from diabetic rats. , 2013, Nan fang yi ke da xue xue bao = Journal of Southern Medical University.

[13]  L. Ferrucci,et al.  Elevated serum fibroblast growth factor 21 is associated with hypertension in community-dwelling adults , 2013, Journal of Human Hypertension.

[14]  Ji A. Seo,et al.  Fibroblast Growth Factor 21: A Novel Metabolic Regulator , 2012, Diabetes & metabolism journal.

[15]  Liping Liu,et al.  Stroke and stroke care in China: huge burden, significant workload, and a national priority. , 2011, Stroke.

[16]  Hao Li,et al.  Using Recombinant Tissue Plasminogen Activator to Treat Acute Ischemic Stroke in China: Analysis of the Results From the Chinese National Stroke Registry (CNSR) , 2011, Stroke.

[17]  Jian Xiao,et al.  Serum Levels of FGF-21 Are Increased in Coronary Heart Disease Patients and Are Independently Associated with Adverse Lipid Profile , 2010, PloS one.

[18]  J. Flier,et al.  Obesity Is a Fibroblast Growth Factor 21 (FGF21)-Resistant State , 2010, Diabetes.

[19]  C. Allen,et al.  Oxidative Stress and Its Role in the Pathogenesis of Ischaemic Stroke , 2009, International journal of stroke : official journal of the International Stroke Society.

[20]  J. Flier,et al.  Fibroblast growth factor 21-deficient mice demonstrate impaired adaptation to ketosis. , 2009, Endocrinology.

[21]  M. Matoulek,et al.  Serum concentrations and tissue expression of a novel endocrine regulator fibroblast growth factor‐21 in patients with type 2 diabetes and obesity , 2009, Clinical endocrinology.

[22]  R. DeFronzo,et al.  Circulating Fibroblast Growth Factor-21 Is Elevated in Impaired Glucose Tolerance and Type 2 Diabetes and Correlates With Muscle and Hepatic Insulin Resistance , 2009, Diabetes Care.

[23]  K. Xiang,et al.  Serum fibroblast growth factor 21 is associated with adverse lipid profiles and gamma-glutamyltransferase but not insulin sensitivity in Chinese subjects. , 2009, The Journal of clinical endocrinology and metabolism.

[24]  D. Moller,et al.  Fibroblast growth factor 21 corrects obesity in mice. , 2008, Endocrinology.

[25]  Feng Liu,et al.  Serum FGF21 Levels Are Increased in Obesity and Are Independently Associated With the Metabolic Syndrome in Humans , 2008, Diabetes.

[26]  M. Pencina,et al.  Evaluating the added predictive ability of a new marker: From area under the ROC curve to reclassification and beyond , 2008, Statistics in medicine.

[27]  P. Dorman,et al.  Impact of functional status at six months on long term survival in patients with ischaemic stroke: prospective cohort studies , 2008, BMJ : British Medical Journal.

[28]  J. Flier,et al.  Hepatic fibroblast growth factor 21 is regulated by PPARalpha and is a key mediator of hepatic lipid metabolism in ketotic states. , 2007, Cell metabolism.

[29]  Yun-Fei Chen,et al.  The metabolic state of diabetic monkeys is regulated by fibroblast growth factor-21. , 2007, Endocrinology.

[30]  J. Gromada,et al.  FGF-21 as a novel metabolic regulator. , 2005, The Journal of clinical investigation.

[31]  T. Kurtz,et al.  Recommendations for blood pressure measurement in animals: summary of an AHA scientific statement from the Council on High Blood Pressure Research, Professional and Public Education Subcommittee. , 2005, Arteriosclerosis, thrombosis, and vascular biology.

[32]  Jun Yang,et al.  Proportion of different subtypes of stroke in China. , 2003, Stroke.

[33]  R. Simon,et al.  Flexible regression models with cubic splines. , 1989, Statistics in medicine.

[34]  E. DeLong,et al.  Comparing the areas under two or more correlated receiver operating characteristic curves: a nonparametric approach. , 1988, Biometrics.